In this study, high-throughput screening and multi-omics (transcriptomics and proteomics) joint analysis technology will be employed to explore potential CTE/TES biomarkers (RNA and protein) in blood and its exosomes. Thereafter, these biomarkers will be combined with the reported TBI biomarkers to create a novel set of CTE/TES molecular diagnostic signatures. The findings may open a new avenue for the clinical diagnosis of the disease and the future research on its therapeutic strategy.
Study Type
OBSERVATIONAL
Enrollment
120
1. Blood tests (30-ml venous blood) for the following items. 1) Transcriptomics and proteomics high-throughput detection and quantitative verification; 2) Exosomal transcriptomics and proteomics high-throughput detection and quantitative verification; 3) Quantitative detection for classical biomarkers of traumatic brain injury, including S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181. 2. Cognitive function tests, including RPQ, MMSE and MoCA. 3. Possible head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Blood level of novel protein biomarkers for CTE/TES
Novel protein biomarkers for CTE/TES will be screened out by transcriptomics + proteomics high-throughput detection and multi-omics bioinformatics analysis. Their levels will be further verified using ELISA assay.
Time frame: Baseline
Blood level of novel RNA biomarkers for CTE/TES
Novel RNA biomarkers for CTE/TES will be screened out by transcriptomics + proteomics high-throughput detection and multi-omics bioinformatics analysis. Their levels will be further verified using RT-PCR.
Time frame: Baseline
Blood level of classical biomarkers for CTE/TES
Blood S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181 level detected by ELISA assay
Time frame: Baseline
Ultrasound examination of the carotid arteries and lower limb arteries
Ultrasound examination of bilateral CCA, ICA, CFA, SFA, PA, DPA and ATA
Time frame: 5 years post-enrollment
Serum Treg cell count and degree of senescence
Percentage of serum regulatory T (Treg) cells relative to the total T cell count; Percentage of senescent Treg cells relative to the total Treg cell count
Time frame: 5 years post-enrollment
Cognitive function tests - RPQ-3
Rivermead post-concussion symptoms questionnaire - 3 (RPQ-3). Reference Range: 0-12. Higher scores mean a worse outcome.
Time frame: 5 years post-enrollment
Cognitive function tests - RPQ-16
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Rivermead post-concussion symptoms questionnaire - 16 (RPQ-16). Reference Range: 0-64. Higher scores mean a worse outcome.
Time frame: 5 years post-enrollment
Cognitive function tests - MoCA
Montreal cognitive assessment (MoCA). Reference Range: 0-30. Higher scores mean a better outcome.
Time frame: 5 years post-enrollment
Cognitive function tests - MMSE
Description: mini-mental state examination (MMSE). Reference Range: 0-30. Higher scores mean a better outcome.
Time frame: 5 years post-enrollment